What it is used for

XTANDI is indicated for:, the treatment of patients with metastatic hormone-sensitive prostate cancer., the treatment of patients with non-metastatic castration-resistant prostate cancer (see PROSPER, section 5.1 Clinical trials)., the treatment of patients with metastatic castration resistant prostate cancer following failure of androgen deprivation therapy in whom chemotherapy is not yet indicated., the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

How to take it

The way to take this medicine is: Oral. This medicine is taken by mouth.

• Store below 25 degrees Celsius
• Shelf lifetime is 3 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

XTANDI 40 mg capsules are supplied as white to off-white oblong soft gelatin capsules imprinted with ENZ in black ink on one side.

Images are the copyright of Medicines Information Pty Ltd

We are currently experiencing issues with Medicines Information data. Images displayed may not be current, please refer to the CMI.

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine. open tool tip to find out more

Is this medicine subsidised?

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy?

For the active ingredient enzalutamide

This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.